Despite the existing evidence that suggested increased risks of ILD in combination osimertinib and anti-PD-(L)1 inhibitors, most of these publications were either retrospective studies conducted in a single institution or early-phase clinical trials with small sample size. This evidence concerns the gene CD274 and interstitial lung disease.